1. About FHI 360
FHI 360 is a nonprofit organization that mobilizes research, resources and relationships so that people everywhere can access the opportunities they need to lead full, healthy lives. FHI 360 serves more than 70 countries and all U.S. states and territories.
2. Detailed Description of Tasks to be Performed:
FHI 360 is currently implementing programs to address challenges in HIV prevention, testing, and treatment, Tuberculosis (TB) case finding and treatment, anti-microbial resistance, health system strengthening, maternal and child health and nutrition, and global health security.
With aims to ensure the financial sustainability of essential drugs for HIV/AIDS treatment in Vietnam, FHI 360 is seeking a qualified and motivated Vietnamese candidate to provide a consultancy service in supporting the HIV/AIDS control program to conduct necessary eco-pharmaceutical studies for selected drug, following update MOH guidance and regulations.
3. Objectives
Specifically, the consultancy aims to:
- Update the existing reports on systematic review of CEA and BIA of single dose dolutegravir (DTG) for children living with HIV/AIDS and PLHIV with TB co-infection.
- Conduct the systematic review on cost effectiveness analysis (CEA) of tenofovir alafenamide (TAF) for HIV treatment following the MOH Decision 1315/QĐ-BYT dated 17 May 2024 (Decision 1315) guiding how to report eco-pharmaceutical studies.
- Develop an executive summary covering the key findings of the CEA and BIA.
4. Scope of work and expected deliverables:
The qualified consultants will conduct the following tasks:
- Participate in meetings with VADP, EpiC/FHI team and key relevant stakeholders to define assessment needs.
- Develop the consultant inception plan to perform the assigned tasks with timeline.
- Update report on systematic review on CEA of DTG and report on budget impact analysis of DTG in Vietnam. In addition, update the summary of these two reports based on updated key findings.
- Conduct the systematic review on the CEA of TAF and develop findings report, following MOH guidance at Decision 1315
- Collect data and analyze the data collected to develop the BIA and its findings report of TAF, following MOH updated guidance at Decision 1315 and in collaboration with VADP.
- Present key findings and update the key findings reports based on feedback from VADP, FHI team and key relevant stakeholders.
- Develop a summary report of CEA report and BIA report for TAF and revise it based on comments from stakeholders.
- Provide a final consultant report in both Vietnamese and English.
- Other relevant tasks as needed.
The Table below summarizes expected deliverables and timelines:
|
Deliverables |
Estimate LOE (days) |
Due date |
|
1. Meeting(s) to discuss objectives and expectations and develop data collection tools |
2 |
31 March 2026 |
|
2. Update reports of systematic review report and budget impact analysis of DTG and its summary |
10 |
20 April 2026 |
|
3. Draft report on systematic review of CEA of TAF |
15 |
15 June 2026 |
|
4. Draft report on BIA of TAF |
15 |
|
|
5. Finalized reports based on comments |
5 |
26 June 2026 |
|
6. Summary of systematic review and budget impact analysis |
3 |
26 June 2026 |
|
Total LOE |
50 |
|
7. Required qualifications
- Advanced degree in public health, health sciences, pharmaceutical sciences, or related fields.
- Strong knowledge and experience in eco‑pharmaceutical analysis
- Experience conducting CEA/BIA studies
- Understanding of HIV treatment needs
- Experience in working with MOH led agencies
- Experience in working with international organizations
- High degree of self-motivation, ability to work independently with tight deadlines
- Excellent communication and interpersonal skills; ability to interact with external and internal audiences of various types and levels;
- Spoken and written fluency required in English and Vietnamese
8. Evaluation Criteria
Applications will be evaluated based on the applicant’s experience and qualifications as detailed above.
9. Required Documentation
Proposals must include the following components:
- Applicants’ CV and highest-level degree
- Cover letter explaining relevant experience in pharmaceutical science, conducting eco-pharmaceutical studies, working with government officials, operating under international donor regulations, and language skills
- Proposed daily rate
- FHI 360 Biodata form
10. Application
- Application to this call should be submitted by email to [email protected] no later than 5PM, March 18, 2026 with the subject line “EpiC-Consultant-Systematic review and budget impact analysis”
- All prospective vendors must comply with the safeguarding policies of our organization. Any violations of the policies may result in immediate contract termination without liability for the organization.
- Only shortlisted applicants will be contacted.
11. FHI 360 Disclaimers
- FHI 360 may perform a background check on any selected vendor.
- FHI 360 may cancel the solicitation and not award.
- FHI 360 may reject any or all responses received.
- Issuance of the solicitation does not constitute an award commitment by FHI 360.
- FHI 360 reserves the right to disqualify any offer based on failure of the offeror to follow solicitation instructions.
- FHI 360 will not compensate any offeror for responding to solicitation.
- FHI 360 reserves the right to issue an award based on initial evaluation of offers without further discussion.
- FHI 360 may choose to award only part of the activities in the solicitation, or issue multiple awards based on the solicitation activities.
- FHI 360 has the right to issue amendments to the RFQ at any time.